An Exploratory Study of the Safety of Substituting Exenatide for Insulin in Patients With Type 2 Diabetes Who Have Been Using Insulin in Combination With Oral Antidiabetic Therapy
Type 2 Diabetes Mellitus
35 Years - 70 Years
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Verified 01 Jan 2015 by AstraZeneca Pharmaceuticals
Eli Lilly and Company
No locations available
The subjects will discontinue their insulin and substitute it with exenatide. Subjects will remain on their existing oral diabetic therapy.
Exenatide 5 mcg subcutaneously injected twice daily for 4 weeks; then 10 mcg subcutaneously injected twice daily for 12 weeks.
Other Name: synthetic exendin-4
Other Name: AC2993
Other Name: Byetta
|Active Comparator: Insulin|
The subjects will remain on their current insulin therapy. Subjects will also remain on their existing oral diabetic therapy.
Insulin will be taken according to the subject's current regimen